NEW YORK – Yingli Pharmaceutical subsidiary 280Bio on Friday said it will begin evaluating its KRAS inhibitor YL-17231 in a Phase I clinical trial involving patients with advanced RAS-mutated tumors.
The company is starting the study after the US Food and Drug Administration cleared its investigational new drug application, giving it the go-ahead to begin evaluating YL-17231 in the US.
The firm expects to begin the Phase I trial during the fourth quarter of this year at US sites, including MD Anderson Cancer Center.
280Bio, which is a South San Francisco-headquartered subsidiary of Shanghai-based Yingli, developed YL-17231 through a collaboration with MD Anderson. Based on preclinical studies, 280Bio believes YL-17231 has antitumor activity across a variety of RAS-mutated cancers, including those that develop resistance to KRAS G12C inhibitors.